Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dostarlimab + bevacizumab + niraparib
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Triplet combination therapy of **dostarlimab**, **bevacizumab**, and **niraparib** is an investigational regimen studied in advanced, platinum-resistant ovarian cancer. Dostarlimab is a monoclonal antibody immune checkpoint inhibitor targeting PD-1, enhancing T cell-mediated anti-tumor response. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), restricting tumor angiogenesis. Niraparib is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), preventing DNA repair in cancer cells with homologous recombination deficiencies. The combination aims to exploit synergistic effects in DNA damage response, immune checkpoint blockade, and anti-angiogenic therapy for improved antitumor activity in heavily pretreated ovarian cancer. Developed and studied primarily for platinum-resistant ovarian cancer, this regimen has demonstrated modest activity in clinical trials, with manageable toxicity profiles consistent with individual agents[1][4][7].
- Brand names
- JemperliZejulaAvastin
- Other names
- dostarlimab + bevacizumab + niraparibniraparib + dostarlimab + bevacizumab
02
Targets
PARP2 (Poly (adp-ribose) polymerase 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on dostarlimab + bevacizumab + niraparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dostarlimab + bevacizumab + niraparib.